SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Beeline Medicines to Present Phase 2 Afimetoran Results at ACR Convergence

Beeline Medicines says it will present results from the Phase 2 afimetoran trial in systemic lupus erythematosus as a late-breaking oral presentation at ACR Convergence 2026.

Story updates

05:26:46 PM UTC
SquawkNews
Results demonstrate consistent improvements across measures of disease activity, quality of life,

Related stories